ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2020
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.Scientific reports · 2023Trial
- Real-world experience of ozanimod in adults with multiple sclerosis.Neurodegenerative disease management · 2026Article
- Prognostic factors in paediatric-onset multiple sclerosis: a narrative review.Journal of neurology · 2026Review
- Validation of rule-based detection methods for relapse in multiple sclerosis.BMC medical informatics and decision making · 2026Article
- Twenty-Four-Month Real-World Outcomes of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Multicenter Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- The importance of patient-reported outcomes: A call for their integration in the routine care of patients with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Review
- Real-World Comparison of High-Efficacy Versus Non-High-Efficacy Therapies in Multiple Sclerosis.Annals of clinical and translational neurology · 2025Observational
- Integrating big data and artificial intelligence to predict progression in multiple sclerosis: challenges and the path forward.Journal of neuroengineering and rehabilitation · 2025Review
- Observational
- Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.Neurodegenerative disease management · 2025Article
- Integrating large language models in care, research, and education in multiple sclerosis management.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Review
- Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte GlycoproteinBalkan medical journal · 2024Observational
- Risk factors and long-term outcomes of oropharyngeal dysphagia in persons with multiple sclerosis: a systematic review protocol.Systematic reviews · 2024Article
- Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.Neurology · 2024Article
- Image harmonization improves consistency of intra-rater delineations of MS lesions in heterogeneous MRI.Neuroimage. Reports · 2024Article
- Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Harmonizing government responses to the COVID-19 pandemic.Scientific data · 2024Article
- The arisal of data spaces: why I am excited and worried.Frontiers in immunology · 2024Article
- Monitoring and Predicting Health Status in Neurological Patients: The ALAMEDA Data Collection Protocol.Healthcare (Basel, Switzerland) · 2023Article
- Improving the efficiency of clinical trials in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized controlled clinical trials and real-world observational studies provide complementary information but with different validity. Some clinical questions (disease behavior, prognosis, validation of outcome measures, comparative effectiveness, and long-term safety of therapies) are often better addressed using real-world data reflecting larger, more representative populations. Integration of disease history, clinician-reported outcomes, performance tests, and patient-reported outcome measures during patient encounters; imaging and biospecimen analyses; and data from wearable devices increase dataset utility. However, observational studies utilizing these data are susceptible to many potential sources of bias, creating barriers to acceptance by regulatory agencies and the medical community. Therefore, data standardization and validation within datasets, harmonization across datasets, and application of appropriate analysis methods are important considerations. We review approaches to improve the scope, quality, and analyses of real-world data to advance understanding of multiple sclerosis and its treatment, as an example of opportunities to better support patient care and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.